MedTrace Logo

Finite Treatment of Hepatitis Delta With Bulevirtide: Identification of Biomarkers Associated With Sustained Control of HDV Infection

NCT06603311 · Status: ACTIVE_NOT_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2026-03-03

No results posted yet for this study

Summary

Finding biomarkers for stopping bulevirtide treatment of patients with hepatitis delta

Conditions

  • Compensated Liver Disease (Disorder)
  • Hepatitis D, Chronic

Interventions

OTHER

Stop Treatment with Bulevertide in patients with compensated liver disease and chronic HDV infection

Stop Treatment with Bulevertide in patients with compensated liver disease and chronic HDV infection who have been treated for at least 48 weeks and reached HDV RNA below 100 IU/ml for at least 24 weeks.

Sponsors & Collaborators

  • German Liver Foundation (DLS)

    collaborator UNKNOWN

  • HepNet Study House, German Liverfoundation

    collaborator NETWORK

  • Hannover Medical School

    lead OTHER

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-09-30
Primary Completion
2026-06-30
Completion
2026-06-30

Countries

  • Germany
  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06603311 on ClinicalTrials.gov